Yoshikazu Kinoshita (Department of Digestive and Hepatic Medicine, Faculty of Medicine, Shimane
University) with regard to the extramural review. Selleck SCH727965 References 1. Goldgerg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22: 23–30.CrossRef 2. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI Selleckchem Saracatinib followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22: 229–37.CrossRefPubMed selleck chemicals 3. Japanese Society for Cancer of the Colon and Rectum: Guidelines for Management of Colon Cancer (for Physicians, Version 2005). Tokyo: Kanehara & Co., Ltd; 2005. 4. Therasse P, Arbuck
SG, Eisenhauer E, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92: 205–216.CrossRefPubMed 5. The advanced colorectal meta-analysis project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10: 893–903. 6. Davis HL: Chemotherapy of large bowel cancer. Cancer 1982, 50: 2638–2646.CrossRefPubMed 7. O’Connell MJ: A phase III trial of 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer. Cancer 1989, 63: 1026–1030.CrossRefPubMed 8. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim Results of a phase III trial. J Clin
Oncol 2003, 21: 2059–2069.CrossRefPubMed 9. de Gramont A, Figer A, Seymour M, Homerin M, Cassidy HJ, Boni C, Cortes-Funes H, Cervantes GBA3 A, Freyer G, Papamichael D, Le Bail N, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18: 2938–2947.PubMed 10. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000, 18: 136–147.PubMed 11.